检索临床试验

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, 法尼基转移酶抑制剂(FTI), 作为单一疗法和联合疗法, 成年晚期实体瘤患者.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-4-500 in patients with advanced cancer

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-3-600 in patients with advanced cancer

这是PRT3789的1期剂量递增研究, 一个SMARCA2降解器, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. 本研究的目的是评价其安全性, 耐受性, 药代动力学(PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, 描述任何剂量限制性毒性(dlt), 确定给药时间表, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789.

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

它旨在回答的主要问题是:

• To assess the safety and 耐受性 of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)
• To assess the safety and 耐受性 of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B)
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• 评价药物的初步疗效
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

参与者将:

• 提供书面知情同意
• Undergo screening tests to ensure they are eligible for study treatment
• Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, 基于参与者在治疗中的表现
• Be followed for progression every 3 months for up to 2 years

这是人类首次(FIH) I/II期, 跨国公司, 多中心, HB-201单载体治疗与HB-201的开放标签研究 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.

This is a dose-escalation and dose-expansion 阶段1/2a trial to evaluate the safety and 耐受性 of DB-1305 in subjects with advanced solid tumors.

这项研究将测试其安全性, 包括副作用, and determine the characteristics of a drug called PRO1184 in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

本研究将分为两部分. Part A of the study will find out how much and how frequently PRO1184 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1184 is and if it works to treat solid tumor cancers.

本研究的目的是评价其安全性, 耐受性, and 药物动力学 of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

这是第三阶段, 多中心, 非盲, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, 输卵管, 或者原发性腹膜癌.

IMGN853-0420是多中心, 非盲, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, 复发性铂敏感, 高级卵巢上皮细胞, 原发性腹膜, or 输卵管 cancer following 1 prior line of platinum-based chemotherapy.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors.

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. 将探讨推荐的2期剂量(RP2D). 每个治疗组接受不同剂量的ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with bevacizumab. 大约500名患有NSCLC的成年参与者, gastroesophageal adenocarcinoma/gastroesophagel junction adenocarcinoma (GEA) and colorectal cancer (CRC) or advanced solid tumors, will be enrolled in the study in approximately 7-10 sites in the Dose Escalation phase and 85-95 sites in the Dose Expansion phase worldwide.

剂量递增武器, participants will receive intravenous (IV) escalating doses of ABBV-400 monotherapy. 剂量膨胀臂, participants in the following advanced solid tumor indications: non-squamous NSCLC with wildtype EGFR-expression (wtEGFR NSCLC) [Part 2i] or mutated EGFR-expression (mutEGFR NSCLC) [Part 2ii], 鳞状非小细胞肺癌[第2iii部分], GEA [Part 3] will receive intravenous (IV) ABBV-400 monotherapy, participants CRC will receive IV ABBV-400 monotherapy in expansion [Part 4], participants MET amplification will receive IV ABBV-400 monotherapy in expansion [Part 5], participants MET mutation will receive IV ABBV-400 monotherapy in expansion [Part 6], participants CRC safety lead in will receive escalating doses of IV ABBV-400 in combination with IV bevacizumab [Part 7a], and participants CRC dose optimization in will the low or high dose of IV ABBV-400 determined in Part 7a in combination with IV bevacizumab or oral trifluridine/tipiracil (TAS-102) tablets [Part 7b].

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, 血液测试, 问卷调查和副作用.

这是第一次人体试验, 阶段1 b / 1, 多中心, 非盲, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

IMGN151-1001是一期产品, 首先是人类, 非盲 dose-escalation and expansion study in adult patients with 复发性 endometrial cancer, 复发性, 卵巢高级别浆液上皮, 原发性腹膜, 或者输卵管癌.

一个First-in-Human, 多中心, 阶段1/2, 开放-Label Study of XTX202 in Patients with Advanced Solid Tumors

该研究尚未在ClinicalTrials上注册.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• 如果您需要临床试验方面的帮助.注册肿瘤学研究，请联系 Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• 如果您需要临床试验方面的帮助.gov registration for a non-oncology study, please contact the 监管事务办公室.

第一部分:剂量递增. The primary objective of Part 1 of this study is to evaluate the safety and 耐受性 of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).

第二部分:群体扩张. The primary objective of Part 2 of this study is to further evaluate the safety and 耐受性 of KB-0742 in defined participant cohorts.